TOMS’ 6th Annual One Day Without Shoes To Take Place On April 16, 2013

— Millions Around the World Unite to Bring Global Awareness to Children’s Health and Education by Going Without Shoes
LOS ANGELES /PRNewswire/ — On Tuesday, April 16, TOMS will ask the world to go without shoes for its anticipated annual One Day Without Shoes event. This is the day each year that TOMS (www.TOMS.com) raises awareness about children’s health and education. Events will take place globally in New York, Los Angeles, Toronto, London, Amsterdam, Seoul, and Tokyo to name a few major cities.
One Day Without Shoes calls attention to three key issues that affect a child’s development around the world — health, education, and self-esteem. Millions of children around the world live without proper footwear, exposing them to injury, infection and disease every day. Shoes help protect kids’ feet and providing uniforms and shoes can help increase a child’s school attendance. Meeting the basic needs of children can increase confidence, leading to better opportunities.
Participants are encouraged to take part by doing whatever they do during the day — just without shoes. One Day Without Shoes supporters can go to http://www.OneDayWithoutShoes.com to get all of the latest updates, create and join events in their area, download an event tool kit, and upload photos. Anyone can join the online conversation by using #withoutshoes to see how others around the world are supporting this day.
TOMS’ founder and chief shoe giver Blake Mycoskie said, “It’s humbling to think that One Day Without Shoes started on a college campus six years ago and now we’re seeing participation from thousands across the globe. Join us on this special day — kick off your shoes and call attention to the many children who have no choice but to go without shoes every day.”
For more information visit: http://www.OneDayWithoutShoes.com
About TOMS:
In 2006, American traveler Blake Mycoskie befriended children in a village in Argentina and found they had no shoes to protect their feet. Wanting to help, he created TOMS, a company that would match every pair of shoes purchased with a pair of new shoes given to a child in need. One for One.®
Five years later, TOMS realized this movement could serve other basic needs and launched TOMS Eyewear. With every pair purchased, TOMS will help give sight to a person in need. One for One.® As more everyday choices have the power to impact the lives of those around the world, the TOMS movement will continue to grow and evolve.
Source: TOMS

The Canadian pharmaceutical company Duchesnay Inc. sets for international expansion following the US approval of its morning sickness medication Diclegis(R) by the FDA

BLAINVILLE, Quebec/PRNewswire/ — Following the US approval of its morning sickness medication Diclegis by the US Food and Drug Administration (FDA), the Canadian pharmaceutical company Duchesnay Inc. is proud to announce that this approval sets the obstetric medicine specialty company for international expansion.
Diclegis has been available in Canada under the trade name Diclectin® for more than 30 years as the only prescription drug specifically indicated and approved for the management of nausea and vomiting of pregnancy (NVP), also known as morning sickness. Diclegis® will be commercialized in the US by Duchesnay USA based in Rosemont, Pennsylvania. The FDA granted Pregnancy Category “A” status to Diclegis, which means the results of controlled studies have not shown an increased risk to an unborn baby during pregnancy.
“The US approval of the patented drug Diclegis, (Diclectin in Canada) by the FDA represents an important milestone for Duchesnay as we plan for strategic expansion through international partnerships. We will leverage our long-standing and prominent expertise as an obstetric medicine company to reach key markets in Europe, Asia-Pacific and Latin America, where millions of pregnant women could beneficiate from our health products,” stated Eric Gervais, Executive Vice-president of Duchesnay Inc.
ABOUT DICLECTIN
Diclectin delayed-release combination of doxylamine succinate and pyridoxine hydrochloride is the only prescription antinauseant and antiemetic drug labeled and approved in Canada for use in pregnancy. Its long and outstanding track record of safety and efficacy has made Diclectin the drug of choice in Canada in the clinical guidelines of the Motherisk Program at the Hospital for Sick Children in Toronto and the Society of Obstetricians and Gynaecologists of Canada (SOGC). Diclectin has been used by over two million pregnant women in Canada.
ABOUT NAUSEA AND VOMITING OF PREGNANCY (NVP)
Nausea and vomiting of pregnancy (NVP), commonly called morning sickness, affects between 70 to 85 percent of pregnant women with symptoms ranging from nausea to severe vomiting and retching that can last throughout the day. Some pregnant women may experience symptoms throughout their pregnancy. If left untreated, symptoms can sometimes progress to a potentially more serious condition called hyperemesis gravidarum (HG), which may require hospitalization. NVP can have a dramatic impact on the emotional and physical well-being of the expectant woman and her family. NVP has also been shown to impose an economic burden on healthcare system and productivity lost.
ABOUT DUCHESNAY
Duchesnay Inc. is a privately held Canadian pharmaceutical company dedicated to improve the health and quality of life of pregnant women and to the advancement of maternal-fetal medicine and scientific research to reduce the risk of birth defects. Duchesnay develops safe and effective pharmacological solutions for use during pregnancy and breastfeeding. For more information, visit http://www.duchesnay.com.
For further information:
Christine Walter, Media relations: (B-roll available upon request) +1-450-433-7734 / mobile: +1-514-895-8798, cwalter@duchesnay.com
Source: Duchesnay Inc.